# EDGAR Filing Document

**Accession Number:** 0001643918
**File Stem:** 0000000000-25-008685
**Filing Date:** 2025-8
**Character Count:** 4072
**Document Hash:** d1e4eaffa7094cb91295b83ed60825ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008685.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0000000000-25-008685

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250818

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biodexa Pharmaceuticals Plc
- **CENTRAL INDEX KEY:** 0001643918
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-37652

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **PROVINCE COUNTRY:** X0
- **ZIP:** CF10 4DQ
- **BUSINESS PHONE:** 44 (0)1235 888300

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 1 CASPIAN POINT
- **STREET 2:** CASPIAN WAY
- **CITY:** CARDIFF
- **PROVINCE COUNTRY:** X0
- **ZIP:** CF10 4DQ

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Midatech Pharma Plc
- **DATE OF NAME CHANGE:** 20150602
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001214659-25-005742

## Text-Extract

```

                                                            August 18, 2025

Stephen Stamp
Chief Executive Officer
Biodexa Pharmaceuticals plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ, United Kingdom

       Re: Biodexa Pharmaceuticals plc
           Form 20-F for Fiscal Year Ended December 31, 2024
           File No. 001-37652
Dear Stephen Stamp:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment.

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 20-F for Fiscal Year Ended December 31, 2024
Operating and Financial Review and Prospects
A. Operating Results
Year Ended December 31, 2024 Compared to Year Ended December 31, 2023, page 83

1.     We note from your pipeline chart, on page 57, that eRapa, Tolimidone,
and MTX110
       are each in clinical development for one or more indications. In your
future filings,
       please expand your disclosure to include the costs incurred, during each
period
       presented, for each of your key research and development product
candidates by
       specific indication separately. If you do not track your research and
development costs
       by project, program, or indication, please disclose that fact, and
explain why you do
       not maintain and evaluate research and development costs by project,
program, or
       indication. For amounts that are not tracked by product candidate,
program, or
       indication, provide other quantitative or qualitative disclosure that
provides more
       transparency as to the type of research and development expenses
incurred (i.e. by
       nature or type of expense), which should reconcile to total research and
development
 August 18, 2025
Page 2

       expense as presented on the Statements of Comprehensive Income. Provide
draft
       disclosure with your response.
        In closing, we remind you that the company and its management are
responsible for
the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.

       Please contact Tracie Mariner at 202-551-3744 or Kevin Vaughn at
202-551-3494
with any questions.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._